5,175 results match your criteria bupropion

Frequently Reported Adverse Events With Smoking Cessation Medications: Post Hoc Analysis of a Randomized Trial.

Mayo Clin Proc 2021 Jun 7. Epub 2021 Jun 7.

Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address:

Objective: To compare the incidence, severity, and clinical course of frequently reported adverse events (AEs) after treatment with smoking cessation pharmacotherapies.

Methods: This was a multinational, multicenter, post hoc analysis of frequently reported treatment-emergent AEs from a large, phase 4, double-blind, randomized, triple-dummy, placebo-controlled trial (EAGLES), conducted between November 30, 2011, and January 13, 2015, that included smokers with and without psychiatric disorders (N=8144). Treatments were varenicline 1 mg twice daily, bupropion sustained-release 150 mg twice daily, and nicotine patch 21 mg once daily with tapering (12-week treatment, 12-week nontreatment follow-up), with incidence, time to onset, and duration of frequently reported AEs (≥5% of participants in any treatment group) measured. Read More

View Article and Full-Text PDF

Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan.

Pharmacoecon Open 2021 Jun 9. Epub 2021 Jun 9.

Department of Clinical Pharmacy, University of California-San Francisco School of Pharmacy, San Francisco, CA, USA.

Background: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans.

Objective: The aim of this study was to characterize trends in smoking cessation medication utilization between 2006 and 2017 within a Medicaid population and estimate per-member per-month (PMPM) costs to the health plan.

Methods: This study was a retrospective longitudinal analysis conducted among adult members of a Medicaid managed care plan in California. Read More

View Article and Full-Text PDF

Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.

Clin Pharmacol Drug Dev 2021 Jun 9. Epub 2021 Jun 9.

Clinical NCA & PK/PD, Nuventra, Inc., Durham, North Carolina, USA.

Napabucasin is an orally administered reactive oxygen species generator that is bioactivated by the intracellular antioxidant nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1. Napabucasin induces cell death in cancer cells, including cancer stem cells. This phase 1 study (NCT03411122) evaluated napabucasin drug-drug interaction potential for 7 cytochrome P450 (CYP) enzymes and the breast cancer resistance protein transporter/organic anion transporter 3. Read More

View Article and Full-Text PDF

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.

Int J Obes (Lond) 2021 Jun 3. Epub 2021 Jun 3.

Bausch Health, Laval, QC, Canada.

Background: Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents. Read More

View Article and Full-Text PDF

Diets and drugs for weight loss and health in obesity - An update.

Biomed Pharmacother 2021 May 31;140:111789. Epub 2021 May 31.

Norwegian Institute of Public Health, P.O. Box 222 Skøyen, N-0213 Oslo, Norway.

Numerous combinations of diets and pharmacological agents, including lifestyle changes, have been launched to treat obesity. There are still ambiguities regarding the efficacies of different approaches despite many clinical trials and the use of animal models to study physiological mechanisms in weight management and obesity comorbidities, Here, we present an update on promising diets and pharmacological aids. Literature published after the year 2005 was searched in PubMed, Medline and Google scholar. Read More

View Article and Full-Text PDF

Evaluating the Machine Learning Literature: A Primer and User's Guide for Psychiatrists.

Am J Psychiatry 2021 Jun 3:appiajp202020030250. Epub 2021 Jun 3.

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, and Olive View-UCLA Medical Center, Sylmar (Grzenda); Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham (Kraguljac); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry, University of Texas Dell Medical School, Austin (Nemeroff); Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (Torous); Department of Psychiatry and Behavioral Sciences, Albert Einstein School of Medicine, Bronx, N.Y. (Alpert); Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, Calif., and Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif. (Rodriguez); Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis (Widge).

"Mr. A," a 24-year-old man, presents for evaluation of worsening depression. He describes a history of depression since adolescence, although he notes that he suffered a troubled childhood, including emotional neglect. Read More

View Article and Full-Text PDF

Current Intervention Treatments for Food Addiction: A Systematic Review.

Behav Sci (Basel) 2021 May 23;11(6). Epub 2021 May 23.

School of Health Sciences, College of Medicine, Health and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.

Research on the concept of food addiction (FA) has steadily grown and, based on a widely used self-report, FA is estimated to affect between 16-20% of the adult population. However, there are few interventions available for people with self-reported FA, and their efficacy is unclear. The primary aim of the review was to examine the efficacy of different interventions, including behavioural/lifestyle, medication and surgical approaches, for reducing symptoms and/or changing diagnosis of FA among adolescents and adults. Read More

View Article and Full-Text PDF

Multidisciplinary barriers to addressing tobacco cessation during an inpatient psychiatric hospitalization.

Addict Behav 2021 Sep 15;120:106988. Epub 2021 May 15.

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Tobacco use and resultant health complications disproportionately impact individuals with psychiatric disorders. Inpatient psychiatric hospitalizations provide an opportunity to initiate tobacco treatment. In this study, electronic medical record review identified demographic and clinical information, smoking status, and tobacco cessation treatment offered for adults hospitalized on two acute, non-smoking psychiatric units in Massachusetts from January 2016 to March 2018. Read More

View Article and Full-Text PDF
September 2021

Bupropion-induced acute dystonia in a patient with bulimia nervosa: A case report.

J Family Med Prim Care 2021 Feb 27;10(2):1034-1036. Epub 2021 Feb 27.

Department of Psychiatry, Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi, University of Medical Sciences, Yazd, Iran.

Bupropion is taken as an antidepressant for treatment of major depressive disorders, treatment of sexual side effects of selective serotonin reuptake inhibitors, and as a smoking cessation aid, however, it may result in adverse effects such as nausea, dry mouth, headache, insomnia, dizziness, anxiety, tremor, and constipation. We investigate the case of a 34-year-old woman with bulimia nervosa where acute dystonia was induced by bupropion in 8 months. Following this diagnosis and after normal tests and MRI results, the patient was advised to discontinue bupropion intake. Read More

View Article and Full-Text PDF
February 2021

Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting.

BMJ Open 2021 05 25;11(5):e042417. Epub 2021 May 25.

Department of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institutte of Pharmacy, University of Groningen, Groningen, The Netherlands.

Objectives: To evaluate the real-world association between varenicline and neuropsychiatric adverse events (NPAEs) in general and chronic obstructive pulmonary disease (COPD) population with and without psychiatric disorders compared with nicotine replacement therapy (NRT) to strengthen the knowledge of varenicline safety.

Design: A retrospective cohort study.

Setting: Prescription database IADB. Read More

View Article and Full-Text PDF

Evidence against e-cigarettes for smoking cessation.

J Am Pharm Assoc (2003) 2021 May 6. Epub 2021 May 6.

Electronic cigarettes (e-cigarettes) have been touted as a safer alternative to cigarettes and even as a smoking cessation aid. The health risks associated with smoking are well known, and smoking cessation has been studied extensively with options including behavioral therapy and pharmacotherapy (nicotine replacement therapy [NRT], varenicline, and bupropion). Several studies analyzed the effects of e-cigarettes as a smoking cessation aid. Read More

View Article and Full-Text PDF

Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.

Syst Rev 2021 May 25;10(1):154. Epub 2021 May 25.

Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital -- Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Background: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide. Antidepressants are frequently used to treat major depressive disorder. It has been shown repeatedly that antidepressants seem to reduce depressive symptoms with a statistically significant effect, but the clinical importance of the effect sizes seems questionable. Read More

View Article and Full-Text PDF

Cue restricted smoking increases quit rates with varenicline.

Tob Prev Cessat 2021 12;7:33. Epub 2021 May 12.

Department of Preventive Cardiology, Oslo University Hospital, Oslo, Norway.

Introduction: Varenicline effectively helps smokers quit by reducing withdrawal symptoms and blocking the reward of smoking. However, most quitters return to smoking within one year. 'Cue Restricted Smoking' is a behavioral technique designed to increase quit rates by asking smokers attempting to quit to restrict smoking to the standing position, while alone, in an isolated area facing a wall, with the cigarette as the only stimulus. Read More

View Article and Full-Text PDF

The pharmacokinetics of gefitinib in a Chinese Cancer population group: a virtual clinical trials population study.

J Pharm Sci 2021 May 17. Epub 2021 May 17.

Aston Pharmacy School, College of Health and Life Sciences, Aston University, Birmingham, B4 7ET, United Kingdom. Electronic address:

Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China and are expected to increase over the next decade. CYP 2D6 intermediate metaboliser (IM) phenotypes are more prevalent in the Chinese population compared to Caucasians; the increased risk of drug-drug interactions (DDI) with chemotherapy polypharmacy may lead to different clinical pharmacokinetics outcomes for Chinese patients. Read More

View Article and Full-Text PDF

Development of Insomnia Associated With Different Formulations of Bupropion.

Prim Care Companion CNS Disord 2021 Feb 18;23(1). Epub 2021 Feb 18.

Division of Pulmonary, Critical Care, and Sleep Medicine, Louis Stokes VA Medical Center, Cleveland, Ohio.

View Article and Full-Text PDF
February 2021

Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight.

J Affect Disord 2021 Jun 23;289:167-176. Epub 2021 Apr 23.

Bausch Health, Laval, QC, Canada.

There is significant association between obesity and depression. Naltrexone/Bupropion (NB) is indicated for treatment of overweight and obesity (BMI ≥27 kg/m with a comorbidity or ≥30 kg/m). This post-hoc analysis examines safety and efficacy of NB and placebo among individuals with overweight or obesity who were also taking antidepressant therapy during the LIGHT trial (N=8910). Read More

View Article and Full-Text PDF

Differential Impact on Isolated REM Sleep without Atonia by Varying Antidepressant Therapies.

J Affect Disord Rep 2020 Dec 25;1. Epub 2020 Sep 25.

Mayo Center for Sleep Medicine, Mayo Clinic, Rochester, Minnesota.

Background: REM sleep without atonia (RSWA) is characterized by increased phasic or tonic muscle activity in electromyography channels during polysomnography and usually causes REM sleep behaviour disorder, but RSWA also exists within healthy populations without dream-enactment behaviour, especially in psychiatric populations receiving antidepressant therapies. Evidence for differential impact of antidepressants on RSWA, and whether RSWA persists or resolves following changes in antidepressant therapy, remains limited.

Case: We present a 56-year-old woman with depression undergoing 3 polysomnograms while receiving 3 different distinct antidepressants. Read More

View Article and Full-Text PDF
December 2020

Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017.

J Neural Transm (Vienna) 2021 May 11. Epub 2021 May 11.

Department of Psychiatry and Psychotherapy, LMU University Hospital Munich, Munich, Germany.

Data on drug prescription for outpatients with major depressive disorder (MDD) suggest women are more likely to be treated with psychotropic drugs, while data on sex differences regarding pharmacological treatment of psychiatric inpatients are currently not available. Drug utilization data from the program "Drug Safety in Psychiatry" (German: Arzneimittelsicherheit in der Psychiatrie, AMSP) of 44,418 psychiatric inpatients with MDD were analyzed for sex differences between 2001 and 2017. Sex differences were analyzed using relative risks (RR) and 95% confidence intervals (95% CI). Read More

View Article and Full-Text PDF

Treatments of Sexual Dysfunction in Opioid Substitution Therapy Patients: A Systematic Review and Meta-Analysis.

Int J Med Sci 2021 12;18(11):2372-2380. Epub 2021 Apr 12.

Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia.

Sexual dysfunction is a common condition in the opioid substitution therapy (OST) population. We aimed to determine the efficacy and safety of treatment for sexual dysfunction in the OST population. We searched for interventional studies from Medline, PubMed, and Scopus. Read More

View Article and Full-Text PDF

Pharmacotherapy of obesity: An update.

Pharmacol Res 2021 May 4;169:105649. Epub 2021 May 4.

Center for the Study and the Integrated Management of Obesity, Padova University Hospital, Via Giustiniani 2, 35128 Padova, Italy; Department of Medicine, Internal Medicine 3,University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Several pharmacological approaches to controlling body weight have been developed over the last decades, albeit with limited success. Currently available agents include centrally acting appetite suppressants and peripherally acting compounds. Efficacy and safety of these agents in the clinical setting require a difficult balance. Read More

View Article and Full-Text PDF

Adherence and Efficacy of Smoking Cessation Treatment Among Patients with COPD in China.

Int J Chron Obstruct Pulmon Dis 2021 30;16:1203-1214. Epub 2021 Apr 30.

Tobacco Medicine and Tobacco Cessation Centre, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.

Background: Smoking cessation is a key intervention for all smokers with chronic obstructive pulmonary disease (COPD). Poor treatment adherence is a challenge in clinical practice that might contribute to the lower efficacy of medication (eg, oral drug). However, it is unclear what factors will influence adherence among smokers with COPD. Read More

View Article and Full-Text PDF

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures.

Polymers (Basel) 2021 Apr 30;13(9). Epub 2021 Apr 30.

Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.

In the last decades, the notion of including excipients in the formulations, as inert substances aiding production processes, has changed and they are recently viewed as multifunctional discrete entities. It is now well documented that excipients serve several roles, spreading from the stabilization and modified release, to providing biocompatible properties and targeting moieties. The aim of this study was to develop matrix-based oral drug delivery systems of bupropion hydrochloride (BUP·HCl) and naltrexone hydrochloride (NTX·HCl), suitable for releasing these active substances in a modified manner, providing a stable level of drug release, which is simultaneously therapeutically effective and non-toxic, thus reducing side effects, after a single dose administration, throughout the gastrointestinal tract. Read More

View Article and Full-Text PDF

Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.

J Clin Psychopharmacol 2021 May-Jun 01;41(3):281-285

Department of Forensic Sciences, Oslo University Hospital.

Purpose: The aim of this study was to investigate the potential dose-dependent CYP2D6 inhibition by bupropion (BUP) in patients with depression.

Methods: Patients combining BUP with venlafaxine were included from a therapeutic drug monitoring (TDM) database at the Diakonhjemmet Hospital (Oslo, Norway). The O/N-desmethylvenlafaxine metabolic ratio measured in TDM samples was used as a biomarker for CYP2D6 phenotype and was compared between patients treated with BUP 150 mg/d and 300 mg/d or greater. Read More

View Article and Full-Text PDF

Intensive management of obesity in people with severe chronic kidney disease: A review.

Diabetes Obes Metab 2021 Apr 27. Epub 2021 Apr 27.

Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.

Obesity is highly prevalent worldwide, including among people with chronic kidney disease (CKD). The presence of severe and/or end-stage kidney disease complicates the treatment of obesity for several reasons, including restrictions on protein and fluid intake and renal excretion of several medications indicated for the treatment of obesity. The aim of this review is to assess the safety of intensive obesity treatments, such as very-low-energy diets (VLEDs), obesity pharmacotherapy and/or bariatric surgery, in people with end-stage kidney disease. Read More

View Article and Full-Text PDF

Rodent models for nicotine withdrawal.

J Psychopharmacol 2021 Apr 22:2698811211005629. Epub 2021 Apr 22.

Department of Psychiatry, University of Florida, Gainesville, USA.

Background: Animal models are critical to improve our understanding of the neuronal mechanisms underlying nicotine withdrawal. Nicotine dependence in rodents can be established by repeated nicotine injections, chronic nicotine infusion via osmotic minipumps, oral nicotine intake, tobacco smoke exposure, nicotine vapor exposure, and e-cigarette aerosol exposure. The time course of nicotine withdrawal symptoms associated with these methods has not been reviewed in the literature. Read More

View Article and Full-Text PDF

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors.

Addiction 2021 Apr 22. Epub 2021 Apr 22.

Research Department of Behavioural Science and Health, University College London, London, UK.

Background And Aims: Analysed using classical frequentist hypothesis testing with alpha set to 0.05, the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) did not find enough evidence to reject the hypothesis of no difference in neuropsychiatric adverse events (NPSAEs) attributable to varenicline, bupropion, or nicotine patch compared with placebo. This might be because the null hypothesis was true or because the data were insensitive. Read More

View Article and Full-Text PDF

Factors associated with seizure development after bupropion overdose: a review of the toxicology investigators consortium.

Clin Toxicol (Phila) 2021 Apr 21:1-5. Epub 2021 Apr 21.

Oregon Health and Science University, Portland, OR, USA.

Background: Bupropion is an aminoketone antidepressant. A major concern in bupropion toxicity is seizure activity, which can occur up to 24 h from ingestion. It is difficult to predict which patients will have seizures. Read More

View Article and Full-Text PDF

Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses.

Obes Rev 2021 Jun 12;22(6):e13224. Epub 2021 Apr 12.

Department of Cardiology, State University of Campinas, Campinas, Brazil.

Despite being approved for clinical use, evidence of cardiovascular safety (CV) is lacking for treatment with bupropion, naltrexone, or their combination (B-N). The purpose of the study is to determine the relationship between these treatments and the risk of major cardiovascular adverse events (MACE). Phase 3 randomized clinical trials (RCT) evaluating bupropion, naltrexone, or B-N versus control with reported incidence of MACE. Read More

View Article and Full-Text PDF


CNS Spectr 2021 Apr 12:1-2. Epub 2021 Apr 12.

Dubai Police Medical Center and Mediclinic Hospital, Dubai, United Arab Emirates.

View Article and Full-Text PDF